KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4605 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. PMID 37991693 · BioDrugs · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. PMID 37988255 · Allergy · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. PMID 37932236 · Diabetes Obes Metab · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease. PMID 37932155 · Clin Ther · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). PMID 37929318 · Am J Hematol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 37903951 · Ann Surg Oncol · 2024-Jan The record describes a prospective observational cohort study preplanned within a randomized Phase III trial (TAXIS/OPBC-03). While it is oncologic, human, and part of a randomized Phase III, it does not meet the core eligibility criteria: it is not a report of a drug-containing intervention (the focus is surgical technique/IGL), and it does not include a primary or key secondary time-to-event efficacy endpoint. The study reports on surgical performance metrics, not survival or progression outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study. PMID 37871985 · Diabetes Obes Metab · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness of Liposomal Bupivacaine With Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Local Anesthetic for Children Undergoing Ambulatory Urologic Surgery: The Baby ORIOLES Randomized Clinical Trial. PMID 37871332 · J Urol · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Participant Safety in Multisite, Randomized, Double-Blind, Placebo-Controlled Clinical Trials in Hospice/Palliative Care: Data from the Contracted Studies of the Australian National Palliative Care Clinical Studies Collaborative. PMID 37824800 · J Palliat Med · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. PMID 37804344 · Ann Hematol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study. PMID 37794628 · Diabetes Obes Metab · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. PMID 37737952 · BioDrugs · 2024-Jan The study is a randomized Phase III trial with a drug intervention and a primary efficacy endpoint. However, it is not an oncology study (it investigates spondyloarthritis) and does not have a time-to-event primary or key secondary endpoint. Therefore, it fails the fundamental oncology and time-to-event criteria for the cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial. PMID 37713021 · Paediatr Drugs · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. PMID 37625434 · Lancet Infect Dis · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis. PMID 37455237 · J Cyst Fibros · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. PMID 37345861 · Int Forum Allergy Rhinol · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. PMID 37061109 · Clin Gastroenterol Hepatol · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Acceptability, feasibility and preliminary efficacy of low-moderate intensity Constraint Induced Aphasia Therapy and Multi-Modality Aphasia Therapy in chronic aphasia after stroke. PMID 37036031 · Top Stroke Rehabil · 2024-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. PMID 38381664 · N Engl J Med · 2024-Feb-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. PMID 37962077 · N Engl J Med · 2024-Feb-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 38416865 · J Clin Psychiatry · 2024-Feb-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. PMID 38295339 · Neurology · 2024-Feb-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial. PMID 38346442 · Lancet · 2024-Feb-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study. PMID 36849205 · Br J Ophthalmol · 2024-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cefepime-Taniborbactam in Complicated Urinary Tract Infection. PMID 38354140 · N Engl J Med · 2024-Feb-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. PMID 38267330 · Vaccine · 2024-Feb-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. PMID 37506264 · J Infect Dis · 2024-Feb-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial. PMID 38348724 · Acta Derm Venereol · 2024-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. PMID 38310910 · Lancet · 2024-Feb-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines. PMID 38001050 · Eur Heart J Acute Cardiovasc Care · 2024-Feb-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. PMID 38324483 · N Engl J Med · 2024-Feb-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials. PMID 37875349 · Sleep · 2024-Feb-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. PMID 38240204 · J Am Heart Assoc · 2024-Feb-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. PMID 38335000 · JAMA Netw Open · 2024-Feb-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. PMID 38281499 · Lancet · 2024-Feb-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults. PMID 38294972 · N Engl J Med · 2024-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial. PMID 38227308 · JAMA Neurol · 2024-Feb-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. PMID 38117487 · JAMA Dermatol · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. PMID 38314063 · Influenza Other Respir Viruses · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial. PMID 38310894 · Lancet Healthy Longev · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. PMID 38245116 · Lancet Glob Health · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. PMID 38224701 · Lancet Oncol · 2024-Feb The trial is a randomized, phase 3, oncology study with a drug intervention and original results. However, the primary endpoint is 'complete control' (a categorical, symptom-based efficacy measure at 120 hours), not a time-to-event outcome such as overall survival, progression-free survival, or any other survival metric. No time-to-event analysis (e.g., Kaplan-Meier, hazard ratio) is reported. Therefore, it does not meet the cohort's requirement for a primary or key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. PMID 38216351 · Clin Ther · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. PMID 38184949 · Epilepsy Behav · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial. PMID 38184428 · Mol Genet Metab · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial. PMID 38142697 · Lancet Respir Med · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID 38142695 · Lancet Haematol · 2024-Feb The study is a randomized, double-blind, phase 3 trial of a drug intervention in an oncology context (HSCT recipients). However, the primary efficacy endpoint is the proportion of participants developing clinically significant CMV infection (a binary outcome) by week 28, not a time-to-event endpoint such as overall survival or progression-free survival. No Kaplan-Meier analysis or hazard ratio is reported for the primary efficacy endpoint. Therefore, it does not meet the inclusion criteria for a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. PMID 38141637 · Lancet HIV · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intrarectal injections of botulinum toxin versus placebo for the treatment of urge faecal incontinence in adults (FI-Toxin): a double-blind, multicentre, randomised, controlled phase 3 study. PMID 38128556 · Lancet Gastroenterol Hepatol · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control clinical trial. PMID 38108468 · Neurourol Urodyn · 2024-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -